Astellas puts gene therapy at heart of R&D strategy

31 March 2021

Japanese company Astellas (TYO: 4503) has become the latest drugmaker to make genetic regulation one of the primary focuses of its research and development (R&D) strategy.

The group has announced plans to further integrate its wholly-owned subsidiary, Audentes Therapeutics, and establish Astellas Gene Therapies within the organization.

This will involve further advancing Astellas’ activities in R&D, manufacturing and commercialization of the associated programs with a foundation in adeno-associated virus (AAV)-based gene therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK